Company Overview - Artivion, Inc. is a medical device company headquartered in suburban Atlanta, Georgia, focusing on solutions for cardiac and vascular surgeons dealing with aortic diseases [3] - The company offers four major product groups: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues [3] - Artivion markets and sells its products in over 100 countries worldwide [3] Upcoming Event - Artivion will participate virtually in the 23rd Annual Needham Virtual Healthcare Conference [1] - The virtual fireside chat is scheduled for April 8, 2024, at 10:15 a.m. ET [1] - A live webcast of the event will be available on Artivion's website, with an archived version accessible for 90 days [2]

Core Viewpoint - Artivion (AORT) has shown strong stock performance, with a 9.6% increase over the past month and an 18.3% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Instruments industry [1][2]. Financial Performance - Artivion has consistently exceeded earnings expectations, reporting an EPS of $0.11 against a consensus estimate of $-0.13 in its last earnings report [2]. - For the current fiscal year, Artivion is projected to achieve earnings of $0.26 per share on revenues of $388.9 million, reflecting a 30% increase in EPS and a 9.86% increase in revenues [2]. - The next fiscal year forecasts earnings of $0.58 per share on revenues of $427.05 million, indicating a year-over-year change of 123.08% in EPS and 9.81% in revenues [2]. Valuation Metrics - Artivion's current trading metrics show a P/E ratio of 81.4X for the current fiscal year, significantly higher than the peer industry average of 27X [4]. - On a trailing cash flow basis, Artivion trades at 27.5X compared to the peer group's average of 15X, suggesting a premium valuation [4]. - The stock has a Value Score of C, a Growth Score of B, and a Momentum Score of D, resulting in a combined VGM Score of B [3]. Zacks Rank - Artivion holds a Zacks Rank of 1 (Strong Buy), driven by rising earnings estimates, making it a favorable investment choice [5]. - The recommendation is to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, which applies to Artivion [5]. Industry Comparison - In comparison to industry peers, Tactile Systems Technology, Inc. (TCMD) also shows strong performance with a Zacks Rank of 2 (Buy) and robust earnings growth [6]. - TCMD is expected to post earnings of $0.56 per share on revenues of $302.89 million for the current fiscal year, with a recent earnings surprise of 192.31% [6]. - The Medical - Instruments industry is performing well, ranking in the top 22% of all industries, providing a favorable environment for both AORT and TCMD [6].

As many know, small-caps’ volatile nature can sometimes turn investors away.However, many small-cap stocks turn out to be big winners in the long run, and they typically have fewer eyes on them, providing investors an opportunity to get in "early" before the crowd.For those seeking exposure to small-caps, three stocks – EZCORP (EZPW) , Artivion (AORT) , and QuickLogic (QUIK) – could all be considered.All three sport a favorable Zacks Rank, indicating optimism among analysts. Let’s take a closer look at each ...

The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth.The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and mi ...

Company Performance - Artivion (AORT) has returned 11.4% year-to-date, outperforming the average gain of 7.8% in the Medical group [2] - The Zacks Consensus Estimate for AORT's full-year earnings has increased by 2500% over the past three months, indicating improved analyst sentiment [2] - Artivion holds a Zacks Rank of 1 (Strong Buy), suggesting strong potential for future performance [1] Industry Comparison - Artivion is part of the Medical - Instruments industry, which has an average gain of 8.9% this year, indicating that AORT is performing better than its industry peers [3] - Another notable stock, Astria Therapeutics, Inc. (ATXS), has returned 89.2% year-to-date and has a Zacks Rank of 2 (Buy) [2] - The Medical - Biomedical and Genetics industry, to which Astria belongs, has only gained 2.9% year-to-date, showing a significant difference in performance compared to Artivion's industry [3]

ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2417093 (State or other jurisdiction of incorpo ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Artivion is one of 1067 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Ran ...

Shares of Artivion (AORT) have been strong performers lately, with the stock up 15.9% over the past month. The stock hit a new 52-week high of $19.63 in the previous session. Artivion has gained 9.5% since the start of the year compared to the 6% move for the Zacks Medical sector and the 4.4% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last ...

Group 1: Stock Performance and Price Targets - Artivion (AORT) closed at $18.70, with a 6.3% gain over the past four weeks, and a mean price target of $24.44 indicating a 30.7% upside potential [1] - The average price target ranges from a low of $22 to a high of $25.75, with a standard deviation of $1.66, suggesting a relatively high agreement among analysts [1][4] - The lowest estimate indicates a 17.7% increase, while the most optimistic estimate points to a 37.7% upside [1] Group 2: Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising AORT's earnings estimates higher, which correlates with potential stock price increases [5] - The Zacks Consensus Estimate for the current year has increased by 2500%, reflecting positive sentiment among analysts [5] - AORT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [6] Group 3: Limitations of Price Targets - Price targets set by analysts can often mislead investors, as empirical research indicates they rarely predict actual stock price movements [3][4] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [3] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [4]